Introduction, disclosures

Review of ATTR [Learning Objective #1]  Brief epidemiology  Pathophysiology   Role of transthyretin  Amyloidosis  ATTR genetics

ATTR Diagnostic Methods  Common complications [Learning Objective #2]  Cardiomyopathy  Polyneuropathy  Kidney disease  Ophthalmologic disease  Musculoskeletal involvement  Differential diagnosis [Learning Objective #3]  Disease mimics  Evaluation and laboratory testing  Imaging  Imaging tests [Learning Objective #3]  Conventional imaging options  Role of new and emerging techniques  Staging ATTR [Learning Objective #3]

Treatment in patients with ATTR [Learning Objective #4]  ATTR polyneuropathy  Patisiran, vutrisiran  Inotersen  ATTR cardiomyopathy  Tafamidis  Off-label treatment options  Drugs in development: eplontersen  Best practice: putting it all together  Patient case(s)

Summary, conclusions, and best practice recap

By the end of the session the participant will be able to:

• Describe the etiologies of ATTR and the role of transthyretin buildup in the symptoms of amyloidosis.
• Review the complications associated with ATTR and the most common presenting symptoms of disease.
• Discuss recommended evaluations for diagnosing, staging, and monitoring ATTR and its complications.
• Develop an appropriate pharmacotherapeutic plan for slowing ATTR disease progression.

ACCME Activity #202583793

ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.

As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.

Disclosures of Faculty: Kourosh Rezania, MD, Associate Professor of Neurology, University of Chicago, has received financial compensation from speaker's bureau of Alnylam Pharmaceutical.

Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.

Faculty WILL NOT discuss off-label uses of a commercial product.

All relevant financial relationships have been mitigated.

ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Commercial Support Disclosure: This program is supported by an educational grant from Alnylam Pharmaceutical.

• Read the learning objectives above
• Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
• View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
• Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
• Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

*Required to view Printable PDF Version